One of the most readily recognized genes associated with monogenic forms of cardiac disease is LMNA, which encodes the intermediate filament proteins lamins A and C, with lamin A being a major component of the nuclear envelope (NE). Several LMNA mutations have been identified in patients displaying a particularly aggressive form of dilated cardiomyopathy (DCM) and conduction system defects, 3, 4 and mutations in the lamin A-binding protein, emerin, cause Emery-Dreifuss Muscular Dystrophy 1 with cardiac conduction defects and atrial arrhythmia. 5, 6 Mutations in additional NE genes have also been proposed as causes of various cardiac disease phenotypes, including the presenilin genes PSEN1 and PSEN2, associated with DCM, and TMEM43, associated with EmeryDreifuss muscular dystrophy 7 and arrhythmogenic right ventricular dysplasia.
F amilial cardiac disease accounts for significant morbidity and mortality worldwide. 1 Many monogenic heritable forms of cardiomyopathy, ion channelopathy, and aortic aneurysm have been documented clinically. A genetic cause has been identified for many cardiovascular disease (CVD) cases previously deemed idiopathic, and multiple genes are now clearly associated with monogenic forms of CVD. Despite this, a significant percentage of putatively familial cases lack a molecular diagnosis, 2 indicating that many genetic contributions to Mendelian forms of CVD remain undiscovered.
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comparison to other gene classes, such as genes encoding sarcomere proteins, or ion channels. The recognition that alterations in NE genes can lead to human disease, including CVD, has created interest in understanding the full repertoire of NE gene mutations seen in humans. 11 Whole exome sequencing (WES) can detect coding variants throughout the genome, and thus offers an opportunity to survey the contribution of numerous genes in suspected monogenic forms of CVD. Accordingly, we screened 55 patients with CVD for pathogenic variants via WES, and identified a molecular diagnosis for over 20% of our cohort. WES also identified candidate mutations in novel disease genes that encode components of the NE. In this report, we describe 4 putative truncating variants in the NE genes NUP37, NUP43, NUP188 and SYNE1 found in patients with severe but distinct cardiovascular conditions.
Methods

Patient Enrollment
Individuals provided informed consent and were enrolled in the NCGENES (North Carolina Clinical Genomic Evaluation by Next Generation Exome Sequencing) study by a certified genetic counselor. Reported variants were Sanger confirmed in UNC's College of American Pathologists and Clinical Laboratory Improvement Amendments-certified clinical molecular genetics laboratory. Reports and clinical interpretation were provided to patients by a board-certified medical geneticist and genetic counselor.
Whole Exome Sequencing
With UNC Institutional Review Board approval, genomic DNA was isolated from whole blood in the UNC Biospecimen Processing Facility. Sample quality and quantity were measured using an Agilent Bioanalyzer or Tape Station. Libraries were prepared using the Agilent SureSelect All Exon V4 kit and paired-end sequenced on a HiSeq2500 at the UNC High Throughput Sequencing Facility at an average depth of 50×, and achieving at least 8× coverage for 98% of all CVD diagnostic genes. Mapping (hg19), alignment, and variant calling were done according to the Broad Institute's best practices using Burrows-Wheeler Aligner and Genome Analysis Toolkit. 12, 13 Variants were computationally annotated and filtered using an in-house bioinformatics pipeline based on genomic position, minor allele frequency (MAF) within the 1000 Genomes database and Exome Aggregation Consortium database (n=61 486 exomes), and predicted protein effect.
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Diagnostic Analysis
Patient WES data were filtered on all gene lists relevant to their phenotype. Diagnostic lists were generated for cardiomyopathy, arrhythmia, and thoracic aortic aneurysm. The diagnostic gene lists were curated from commercial CVD gene panels, Online Mendelian Inheritance in Man entries, and PubMed searches ( Table I in the Data  Supplement) , and variants were annotated with respect to conservation, protein functional domains, and consensus deleteriousness pathogenicity predictions. 15 Variants were classified according to American College of Medical Genetics guidelines. 16 Case-level results were defined as "positive," "negative," or "uncertain" depending on the degree of phenotypic overlap between the patient and the variant(s)/condition identified. 48 Sanger fill-in for hypertrophic cardiomyopathy cases was performed on 2 regions poorly covered by WES: exons 9 and 14 in MYH7 and exon 8 in MYBPC3.
For the research sweep on negative cases, python scripts were used to make Structured Query Language database queries to select rare (MAF <0.001) frame-shift, splice-site, or nonsense variants throughout the whole exome. Evaluation of Panther cellular compartment classifications (release 20150430) in the AmiGO database revealed ontology for genes on our CVD diagnostic lists. Candidate NE variants were also Sanger verified. SYNE1 (F: TCCTTGAATAACGCTTTGTCCA/R: ACTTAGATGTGGG  TAATTCATGCT), NUP37 (F: AGTTTTCTTATTTGTTGTTCCT  ACCT/R: GCCACAACATTCTTCTTTCCC), NUP43 (F: CCACAT  GTTCACAATCTTTTGCC/R: TCACCTGCTTTTCCTGAAGACT) , and NUP188 (F: ACTCTCCTTAGAACAAAAATGGGGA/R: GCATGTTGAGGGCCACATTC).
Cell Culture, Immunofluorescence, and Microscopy
With informed consent and approval from the UNC Institutional Review Board, follow-up blood samples were obtained from NCG_00024 and his father. Peripheral blood lymphocytes were transformed with Epstein Barr virus by the UNC Tissue Culture Facility. Control cells used were GM12765 from Coriell human cell repository. Six thousand cells/well from passage 3 or earlier were plated onto NuNc/LabTekII CC-2-coated chamber slides (Sigma), adhered for 5 days, fixed with 4% paraformaldehyde for 30 minutes, and stained in the chamber slides. Primary antibodies used were rabbit anti-nesprin1 (Sigma; 1:250) and goat anti-lamin A (Millipore; 1:250). Cellular actin was visualized by Alexafluor-conjugated phalloidin (Life Technologies). Alexafluor secondary antibodies were used at 1:2000. Slides were cover slipped with Prolong Gold containing 4′,6-diamidino-2-phenylindole and imaged on a Zeiss AxioImager M2. Samples were blinded and nuclei from 2 separate experiments were scored. Abnormal shapes were defined as micronuclei, blebbed, or irregular nuclei. Normal morphology was defined as a smooth spherical shape. The difference in the number of abnormal cells between control and patient cells was evaluated using Fisher t test.
Expression Analysis
RNA from murine heart and zebrafish embryos was isolated using Trizol or RNeasy mini kit (Qiagen). RNA quality was checked on an Agilent Bioanalyzer, and reverse transcribed using QuantiTect Reverse Transcription Kit (Qiagen) or Superscript III supermix (Invitrogen). One microliter of 1:20 cDNA was used to amplify transcripts using Ssofast Evagreen kit (BioRad). Reactions were run in triplicate, and relative expression levels were compared with ACTB or GAPDH. A 2-way ANOVA was done to compare gene expression and morpholinos, followed by a post hoc Fisher t test for individual morpholinos.
Animal Husbandry
Adult wild-type ICR mice and wild-type and Tg (myl7:green fluorescent protein) twu26 zebrafish were maintained at UNC-CH animal facilities. Embryos were produced and recovered by natural spawning or timed matings (mice) in accordance with Institutional Animal Care and Use Committee protocols. Zebrafish embryos were maintained at 28.5° in system water and treated from 24 hours post fertilization (hpf) with 1-phenyl 2-thoiurea to prevent pigmentation.
Morpholinos
Splice-blocking antisense morpholino oligos (MOs) against syne1b, nup37, and nup43 were designed by and purchased from GeneTools, Inc. Sequences (5′-3′): zsyne1b MO-I, e44i44, CCTGGAAATCAAACTTACCTGTAGT; zsyne1b MO-II, e38i38, GCTCTGAAGATGAAGCGTACCTTGA; znup43 MO-I, e7i7, GCAGCGAAATCATTGCTTACTCTGT; znup43 MO-II, e4i4, ATGCGCCACAAAACACTTACCAATA; znup37 MO-I, e4i4, AAAAAGAGAGCTACCTTCACATCAC; znup37 MO-II, e3i3, ACACAAGTTCAAAACTATACCTGA; and Standard Control MO, CCTCTTACCTCAGTTACAATTTATA. Nup37 and nup43 MO were used at 7 ng, and syne1b MO was used at 8 ng. Zebrafish embryos at the 1 to 2 cell stage were injected with 1 nL of morpholino or 350 pg RNA in water buffered with 5 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid. For RNA-rescue experiments, pCS2 clones containing sequence-verified Nup37 and Nup43 open-reading frames were obtained from the Harvard plasmid repository (HsCD00324272 and HsCD00339012). Full-length mRNA was transcribed using mMessage machine (Ambion), purified, and analyzed with the Tape Station. Nuclear Envelope Gene Mutations in Cardiac Disease
Zebrafish Phenotyping
Unfertilized and dead embryos were removed from dishes within 12 hpf and again at 24 hpf. For phenotyping, 3 dpf embryos were placed 1 per well and scored under a brightfield microscope. The significance of the difference in percentage of animals with pericardial edema under different experimental conditions at 72 hpf was evaluated first using a χ 2 analysis to compare all groups, followed by a 2-tailed Fisher t test at α<0.05 with a bonferroni correction of 0.007. Heart chamber abnormality was evaluated in Tg animals by examining green fluorescent protein-labeled heart chambers at 100×. Any tail curvature was noted. Embryos that died between 24 and 72 hpf were counted as dead. To assess heart rate, 15-s videos were recorded at 30 frames per second on unanesthetized 3 dpf embryos using a Leica M205C fluorescence stereoscope and Leica Application Suite software. Heartbeats were manually scored by a blinded observer and multiplied by 4 to calculate heart rate in beats per minute.
Results
Exome data were obtained from 55 patients enrolled in the NCGENES study. Individuals were referred by a cardiologist with hallmarks of a Mendelian cardiogenetic disease, including severity, age of onset, or positive family history. The cohort reflects the diversity typically encountered clinically; most patients were enrolled for cardiomyopathy or long QT, and patients with thoracic aortic aneurysm or severe mitral valve prolapse, were also enrolled.
Diagnostic Analysis
To investigate WES diagnostic yield of this relatively unselected cohort, we first filtered for variants present in genes associated with the patient's phenotype (Table I in the Data Supplement). These diagnostic lists include genes encoding sarcomeric proteins (38 genes; 36.2% of all genes on the diagnostic lists) and ion channels (17 genes; 16.2% of all genes), molecular classes that are well recognized in CVD pathogenesis. Interestingly, we noted that a substantial number of the other genes on these lists encoded proteins that reside in the NE (7 genes; 6.7%). NE genes were present on all 3 CVD phenotype gene lists: cardiomyopathy (LMNA, EMD, PSEN1, PSEN2, TMEM43, and TMPO), arrhythmia (TMEM43 and EMD), and thoracic aortic aneurysm (SMAD3).
WES variants from all gene lists relevant to the patient's phenotype were examined. Twelve of 55 (21.8%) patients harbored a known or likely pathogenic variant in an established CVD gene, and an additional 19 of 55 patients (34.5%) had an uncertain result ( Figure 1A ). A total of 37 variants were reported to patients, and 16 of these had been previously seen in the primary literature or ClinVar (Table II in the Data Supplement). Individuals with arrhythmia were most likely to get a positive result, whereas only 1 of 11 (12.5%) patients with aneurysms or valvular conditions received a positive result. Cardiomyopathy cases had the greatest number of variant of unclear significance, although variant of unclear significance were encountered in all phenotypic classes ( Figure 1B ).
In agreement with others, we found that TTN truncating variants comprise the bulk of mutations for patients with DCM. 17 Because of the gene's large size, TTN variants are routinely encountered in WES. Because many rare missense variants in TTN could not be excluded as potentially pathogenic, TTN contributed a large number of variant of unclear significance for our cardiomyopathy cohort. We compared the distribution of all TTN MS variants (MAF<0.002 in ExAC) in our entire NCGENES cohort, and found no significant difference in the distribution of TTN MS variants that were rare or had higher combined annotation dependent depletion scores (an in silico prediction of deleteriousness) in cases with DCM compared with 451 controls (NCGENES participants without a cardiovascular phenotype, Figure 1C ; Table III in the Data Supplement) .
Although TTN variants were reported in 10 of 55 cases with CVD, other genes contributed pathogenic variants to only 1 or 2 cases. Two individuals with hypertrophic cardiomyopathy carried distinct pathogenic variants in MYH6, and 2 cases with hypertrophic cardiomyopathy harbored the same rare pathogenic missense variant in MYBPC3 (Table II in the Data Supplement). All other genes explained only 1 case ( Figure 1D ).
Research Analysis
A significant number of cases were negative in our diagnostic analysis (43.6%, Figure 1A ). To identify novel candidate disease-causing variants in these cases, we broadened our analysis to the entire captured exome. Examination of all rare (MAF<0.001) nonsense, splice-site, and frame-shifting variants identified 4 candidate mutations in NE genes ( Figure 2 ). Interestingly, 3 of these predicted loss of function (pLOF) variants were in genes encoding nucleoporins (NUPs), proteins that comprise the nuclear pore complexes. Nuclear pore complexes are multiprotein structures that facilitate nucleocytoplasmic shuttling of mRNAs and proteins, provide structural integrity to the NE, bind other NE components such as lamin A, and may also interact with chromatin. [18] [19] [20] [21] Heterozygous nonsense variants were identified in the nucleoporins NUP37 and NUP43, and a heterozygous consensus splice donor variant was identified in NUP188 (Figures 2  and 3A) . Although each individual in whom these variants were identified was enrolled for an apparently autosomal-dominant form of CVD, each had a distinct phenotype. Candidate variants were Sanger confirmed. Thus, we identified 3 different pLOF variants in nucleoporins in CVD patients with severe, but distinct cardiovascular phenotypes.
We also identified a splice acceptor variant in the NE gene SYNE1 in a 17-year-old male with DCM who underwent heart transplant at the age of 15 years. His father also had DCM and had a left ventricular assist device implanted. SYNE1 has previously been implicated in cardiomyocyte function and cardiomyopathy in mice, as well as a myopathy with variable cardiac and skeletal muscle involvement, Emery-Dreifuss muscular dystrophy 4 (Online Mendelian Inheritance in Man 612998). [22] [23] [24] [25] Both of these individuals were followed clinically for years by a cardiologist and were not noted to have any muscle weakness. The ability to perform cascade testing for these cases was limited; however, the affected father of the subject with severe DCM was available for follow-up analysis. Targeted sequencing showed that the affected father also carries the SYNE1 c.6403-1 splice variant (Figure 2 ).
In Vitro and In Vivo Evaluation of Candidate Disease-Associated NE Genes
The NUP37, NUP188, and SYNE1 variants are not present in the ExAC database of 61 486 exomes, and the NUP43 (R339Ter) variant is rare (MAF=0.00002), indicating these variants cannot be considered benign polymorphisms based on population frequency. Moreover, we found that while 3 of 55 patients with CVD carried a truncating variant of MAF <0.001, none were found in NCGENES participants enrolled for noncardiovascular conditions (n=451, P=0.001, Figure 3B ). These data show that rare pLOF variants in nucleoporins are enriched in patients with CVD.
Very little functional data exist on the nucleoporins we identified, and their expression in heart has not previously been described. To address this, we generated cDNA from adult and embryonic day 11 (E11.0) mouse heart, and screened for expression of our candidate genes. All genes were expressed in both E11.0 and adult mouse heart, and expression levels vary between stage of development and adult heart compartment ( Figure 4A ). Expression of NUP37 was 7-fold higher in atrium versus ventricle, which was notable given the atrial fibrillation phenotype seen in this patient ( Figure 4B ). These data are in agreement with gene expression data found in the Genotype-Tissue Expression database (http://www.gtexportal.org; accessed July 8, 2016) showing that these genes are expressed in human heart.
Mice missing a portion of the SYNE1 gene display abnormal nuclear shape, mislocalization of NE components, and cardiomyopathy. 23 Similar changes have been shown in cells from a patient with cardiomyopathy carrying a SYNE1 missense variant. 24 To determine whether our WES-identified SYNE1 splice-site variant was associated with cytological changes in NE morphology, we analyzed patient lymphoblasts. Nesprin1 protein in control cells was present on the nuclear surface and extended into the cytoplasm ( Figure 5A ). In the patient with DCM, nesprin1 staining was detected in the NE in a pattern similar to control cells, although the staining appeared more confined to the nucleus, and less homogenous, with large nuclear regions devoid of nesprin1 staining ( Figure 5B ). SYNE1-encoded nesprin protein binds to lamin A, a marker of the inner NE, and alterations in lamin A are known to cause DCM, so we examined expression of lamin A protein in patient cells. In contrast to the spherical perinuclear staining in control cells, patient nuclei demonstrated immunoreactive puncta within nuclear blebs and bulges ( Figure 5C and 5D). Patient cells also had a globular pattern of actin in contrast to the well-organized linear arrays of actin typically seen in control cells ( Figure 5E and 5F), consistent with a previously reported role for SYNE1 in proper actin binding, formation, and localization. [25] [26] [27] The number of patient cells with an abnormal nuclear morphology was significantly increased compared with control cells ( Figure 5G ). Thus, examination of cells from the patient carrying a splice-site variant in SYNE1 is consistent with morphological alterations in the NE.
Functional Evaluation of Candidate Genes
The phenotypes of the patients carrying pLOF variants in NE genes suggested that mutations in these genes might preferentially affect cardiovascular development or function, and knockdown of one of the candidate genes, nup188, has previously been shown to result in heart looping defects in Xenopus. 28 We, therefore, investigated the functional role of SYNE1, NUP37, and NUP43 in vivo through morpholino knockdown in zebrafish.
Because zebrafish embryos rely on diffusion to circulate oxygen throughout their bodies for the first several days of life, it is possible to study mutations which severely affect cardiovascular development and circulation, and which ultimately lead to heart failure. Accordingly, zebrafish have become a model organism of choice for investigating the function of candidate CVD genes. 29, 30 We confirmed the presence of zebrafish orthologues of human SYNE1, NUP37, and NUP43, and all are expressed in zebrafish heart during development. Expression of nup37 and 
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nup43 is stable from day 2 to day 3, whereas expression of syne1b increases ≈12-fold from day 2 to day 3, when phenotypic scoring was done and animals were euthanized (data not shown).
Zebrafish embryos injected with 4 nmol/L standard control MO, which does not bind any physiological target, were indistinguishable from uninjected clutch mates ( Figure 6A ). Injection of an antisense (MO) that disrupts splicing of the normal nup37 transcript resulted in reduced nup37 expression at 3 dpf, as well as severe pericardial edema, a characteristic manifestation of zebrafish heart failure, along with reduced blood flow and apparent arrhythmia in some animals ( Figure 6B ; Movie I in the Data Supplement). Injection of the nup37 MO into Tg (myl7:enhanced green fluorescent protein) embryos, 31 which have fluorescently labeled cardiac myocytes, demonstrated abnormalities of the heart chambers in several animals, including small or stretched atrium or malpositioned chambers that had not looped properly ( Figure I in the Data Supplement). A second, independent nup37 morpholino designed against a separate splicing boundary yielded similar results ( Figure I in the Data Supplement). Co-injection of fulllength human NUP37 mRNA rescued the morphant phenotype to a significant extent ( Figure 6G ).
Previously described mutations associated with thoracic aortic aneurysm result in pericardial edema when evaluated in zebrafish.
32 Nup43 morphants also developed the expected pericardial edema, although the proportion was less than in nup37 MO-injected animals ( Figure 6C and 6G) . Fifteen percent of nup43 morphants displayed pericardial edema or heart chambers that were in a linear orientation and seemed to have not fully looped properly ( Figure 6C) ; this phenotype was ameliorated in embryos injected with nup43 MO plus human NUP43 RNA ( Figure 6G ). At 3 dpf, the heart rate of many nup43 morphants appeared slower than control-injected animals. We quantified the apparent difference in heart rate by optical recording of Tg animals injected with either nup43 MO, control MO, or nup43 MO followed by 350 pg NUP43 mRNA. nup43 morphants had a statistically significant slower heart rate than control animals at both 2 and 3 dpf. Co-injection of full-length human NUP43 mRNA significantly ameliorated the bradyarrythmia in nup43-MO injected embryos ( Figure 6F ). Thus, reduced expression of nup37 and nup43 results in cardiovascular defects without any apparent effects on the rest of the body.
The majority of embryos injected with a morpholino targeting syne1b developed severe pericardial edema ( Figure 6D , 6E, and 6G). A small proportion of morphants displayed a curved tail phenotype ( Figure 6E ; Figure II in the Data Supplement), consistent with SYNE1 being implicated in the variable skeletal and cardiac myopathy Emery-Dreifuss muscular dystrophy 4. Heart morphology appeared normal in many syne1b morphants with pericardial edema, whereas some morphants showed small or stretched heart chambers in severely affected animals ( Figure II in the Data Supplement). Many syne1b morphants with pericardial edema had pooled blood and reduced or absent blood flow (Movie II Data Supplement). Rescue with full-length SYNE1 mRNA was not feasible given the length of its 27kb open-reading frame; a second, independent morpholino designed against a separate splicing boundary yielded similar results ( Figure II in the Data Supplement). These results indicate that aberrant expression of NE genes can lead to abnormal cardiac development and heart failure in zebrafish.
Discussion
Diagnostic Analysis
Our results demonstrate that WES has both diagnostic and research use for a diversity of suspected monogenic forms of CVD. WES identified a pathogenic variant in 21.8% of cases with CVD, with diagnostic yield varying among phenotypic classes. Because of lack of uniform coverage for all exons, it is possible that causative variants were missed in this analysis, although most genes showed good coverage across all individuals (Table IV in the Data Supplement). We found a substantial number of novel likely pathogenic variants, and our annotations of these variants in well-phenotyped individuals will aid the clinical interpretation of these variants by future groups. Truncating A-band mutations in TTN are a significant cause of cardiomyopathy, and thus, TTN variants must be evaluated for any patient with DCM undergoing clinical WES. Our analysis found no increase in rare or deleterious TTN MS variants in any region of the gene, in CVD cases compared with non-CVD cases. These results support a growing body of evidence suggesting caution is warranted in interpreting rare TTN missense variants as pathogenic in cases of autosomal dominant cardiomyopathy. 33, 34 Although cardiomyopathy and arrhythmia cases had a relatively high yield, the yield for thoracic aortic aneurysm and mitral valve prolapse cases was much lower, likely because of a smaller number of known disease genes for these phenotypes. We felt strongly that diagnostic results should only be reported in genes with a strong gene-disease association; our yield is, thus, more akin to running a targeted gene panel. A major advantage with the use of WES as a diagnostic tool, as opposed to using a gene panel approach, is that WES allows further investigation of negative cases.
The yield of "uncertain" results in this study is consistent with the experience of practicing clinicians; whereas such results do not change clinical management, they are a valid type of result routinely returned by clinical laboratories and might be useful if an extended pedigree were available for cosegregation studies to allow them to be classified further.
49
Nucleoporins and Cardiac Disease
Unexpectedly, 3 cases in our cohort carried rare pLOF variants in nucleoporin genes not previously associated with CVD, despite truncating variants in these genes being absent in our broader NCGENES cohort, or exceedingly rare in the ExAC database. The sum of all pLOF variants reported in ExAC for NUP37, for example, is <1 in 10 000, indicating that truncating variants in this gene are rare. This is the second report to our knowledge of a nucleoporin associated with familial CVD. Mutations in NUP155 have been implicated in familial atrial fibrillation and sudden death, 35 the same phenotype and family history present in NCG_00096 who carries the NUP37 (R339Ter) variant. NUP37, NUP43, and NUP188 are, like NUP155, scaffold nucleoporins, whose expression is important both for nuclear pore complex assembly and transport function. 19 As NUPs have been shown to play several different mechanistic roles beyond maintaining structural integrity of the NE, including shuttling of specific cargo molecules 36, 37 and interacting with chromatin to regulate gene expression, 20 the exact mechanisms by which the NUP variants could lead to a cardiovascular phenotype remain unclear. Truncating variants producing nonsense-mediated decay would be expected to lead to haploinsufficiency, a mechanism that is supported by morpholino knockdown experiments. Decreased nup188 expression in Xenopus embryos results in heart looping defects, a phenotypic finding we also noted in a subset of our nup37 and nup43 morphants. Alternatively, several of the truncating variants could create proteins missing functional domains, which could result in loss-of-function or possibly dominant-negative effects. Although our zebrafish data indicate a potential role for nucleoporins in cardiovascular development, these proteins are likely to function in adult heart as well, and ultimately, it is difficult to correlate phenotypes seen in fish with phenotypes one would see in a human.
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Nesprin in Cardiomyopathy
The SYNE1-encoded protein nesprin-1 is part of the LINC (Linker of the Nucleus to the Cytoskeleton) complex. Multiple isoforms have been reported for nesprin-1, and at least one heart-specific regulatory element has been described. 26 The NE-anchored nesprin-1 protein responds to mechanical force initiated at the cell surface through its interaction with 39 Studies in mice demonstrate that nesprin-1 coordinates the proper biomechanical gene response in cardiomyocytes and contributes to the cytoskeletal defects in LMNA-deficient cardiomyopathy; heterozygous nesprin mice display cardiac defects (M. Pucklewartz, personal communication 40 ), and SYNE1 variants have been identified in at least 2 families with DCM, with or without skeletal muscle In wild-type animals, the pericardial chamber is in the same plane, whereas edema in morphant animals causes the pericardial chamber to swell significantly outside that plane. Right most panels show quantitative polymerase chain reaction results from control (Ctrl) and MO-injected animals harvested at 3dpf. Asterisks denote statistically significant differences in gene expression using 2-way ANOVA analysis and follow-up t test. E, Representative images of the tail phenotypes seen in some syne1b MO-injected zebrafish. F, The heart rate of nup43 morphants is slower than control zebrafish at 2 and 3 dpf, and this phenotype is significantly rescued in nup43 MO+nup43 mRNA-injected animals. G, Summary of morphant phenotypes. The asterisk designates significant difference, P<0.0001 in the percentage of animals with pericardial edema. involvement. 24, 47 Physical disruption of normal LINC complex interactions is, therefore, a plausible biological mechanism underlying the cardiomyopathy in our patient and father.
The cardiovascular system, which undergoes constantly changing force and pressure, may be particularly vulnerable to alterations in NE components, including nuclear pores and LINC proteins. [41] [42] [43] [44] The phenotype of each patient in our cohort carrying a candidate mutation in these NE genes is distinct, suggesting a spectrum of possible cardiovascular phenotypes dependent on the NE gene affected. Nevertheless, the WES results suggest that human mutations in this gene class may be particularly important for CVD, a conclusion supported by our statistical analysis in non-CVD NCGENES patients, expression analysis in murine heart, and in vitro cell studies, as well as our zebrafish studies, where morphant animals developed cardiovascular phenotypes. Together, our results support the idea that a healthy, intact NE is important for normal heart function and expand the repertoire of genetic variants in NE genes that are associated with cardiogenetic disease.
Few NE genes have been sufficiently studied to establish a strong gene-disease association. We find the association of inner nuclear membrane NE genes is stronger than that of outer nuclear membrane NE genes. The inner nuclear membrane genes LMNA, EMD, SMAD3, and TMEM43 genes are more established as causative according to more rigorous criteria, 45 and numerous reports have upheld a role for these NE genes in CVD. Although multiple lines of evidence are converging to support a role for NE genes in CVD, many of these should still be considered candidate genes until further evidence is generated (Figure 7 ). The NE and nuclear transport have emerged as potential therapeutic targets for modulating genetic programs associated with disease. 46 Identifying individuals with mutations in NE genes that could benefit from these approaches is, therefore, important. Future work will further delineate the spectrum of phenotypes associated with mutations in NE genes and investigate the mechanism by which NE genes, and nucleoporins specifically, contribute to CVD in humans. 
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